Table 3.
Overview of miR-223 experiments and their expression in asthma and COPD.
| Overview of miR-223 experiments | Expression of target genes in asthma and COPD | |||||
|---|---|---|---|---|---|---|
| Expression of miR-223 | Cell type | Condition | References | Asthma | COPD | References |
| Downregulation miR-223 | HBECs | ↑ NF-kB activity | (37) | ↑ NF-kb activity in HBECs | ↑ NF-kb activity in HBECs | (51) |
| Overexpression of miR-223 | HBECs | ↓ PARP-1 | (22) | ↑ PARP-1 activity in PBMCs and lung tissue |
↑ PARP-1 activity in blood | (52, 53) |
| Reduction of miR-223 | Monocytes/Macrophages | ↑ IKKα | (36) | No differences in PBMCs No differences in IKKα activity in PBMCs | No differences in PBMCs ↑ IKKα activity in PBMCs |
(54) |
| Downregulation miR-223 | Basal epithelial cells of zebrafish | ↑ TRAF6 | (37) | No differences in PBMCs | NA | (55) |
| Downregulation miR-223 | HBECs | ↑ CUL1 | (37) | NA | NA | |
| Downregulation miR-223 | HBECs | ↑ TAB2 | (37) | NA | NA | |
| Overexpression of miR-223 | Murine neutrophils/A549 cells | ↓ NLRP3 | (24) | ↑ NLRP3 in sputum of neutrophilic asthma patients | ↑ NLRP3 in PBMCs No differences in HBECs |
(56, 57) |
| Overexpression of miR-223 | A549 cells | ↓ RhoB | (39) | NA | NA | |
| Knock out of miR-223 | Murine lung | ↑ IL-6 | (42) | ↑ IL-6 BALF and sputum | ↑ IL-6 BALF and sputum | (8) |
| Knock out of miR-223 | Murine lung | ↑ CCL3 | (42) | ↑ CCL3 in BALF and CD4+ T cells No differences in BALF ↑ CCL3 in CD8+ T-cells |
↑ CCL3 in sputum | (58–62) |
| Knock out of miR-223 | Murine lung | ↑ CXCL2 | (42) | NA | ↑ CXCL2 in lung tissue | (63, 64) |
| Overexpression of miR-223 | Murine macrophages | ↓ STAT3 | (41) | ↑ STAT3 activity in airway smooth muscle cells | ↑ STAT3 in lung tissue | (65–67) |
| Overexpression of miR-223 | Human coronary artery endothelial cells |
↓ ICAM-1 | (50) | ↑ ICAM-1 in blood, BALF and nasal lavage fluid |
↑ ICAM-1 in lung tissue | (64, 68) |
| Overexpression of miR-223 | human pulmonary artery endothelial cells (HPAEC) | ↓ HDAC2 | (43) | NA | ↓ HDAC2 activity in lung tissue and alveolar macrophages | (69) |
| Knock out of miR-223 | T cells | ↓ Mef2c | (17) | ↓ Mef2c in HBECs | NA | (70) |
| Overexpression of miR-223 | Human adenocarcinoma | ↓ IGF-1R | (44) | ↑ IGF1 signaling in bronchial biopsies | ↓ IGF-1 in serum ↑ IGF-1 in quadriceps |
(44, 57, 61) |
| Knock out of miR-223 | Neutrophils | ↑ IGF-1R | (17) | |||
| Overexpression of miR-223 | Airway smooth muscle cells | ↓ IGF-1R | (46) | |||
| Overexpression of miR-223 | Lewis lung carcinoma cells | ↓ IGF-1R | (45) | |||
| Overexpression of miR-223 | A549 cells | ↓ TGFBR3 | (47) | ↓ TGFBR3 in blood | ↓ TGFBR3 in severe COPD patients | (71, 72) |
| Downregulation miR-223 | SPC-A1 lung cancer cells | ↑ TGFBR3 | (47) | |||
| Overexpression of miR-223 | Human lung squamous cell carcinoma cells |
↓ p53 | (48) | NA | ↑ p53 in lung tissue | (73, 74) |
| Overexpression of miR-223 | Lewis lung carcinoma cells | ↓ CDK2 | (45) | NA | NA | |
BALF, Bronchoalveolar lavage fluid; CCL3, Chemokine (C-C motif) ligand 3; CDK2, Cyclin-dependent kinase 2; CUL, cullin 1; CXCL2, CXCL2, Chemokine (C-X-C motif) ligand 2; HBECs, human bronchial epithelial cells; HDAC2, histone deacetylase 2; ICAM-1, Intercellular adhesion molecule 1; IGF-1R, insulin-like growth factor-1 receptor; IKKα, IκB kinase α; IL-6, Interleukin-6; Mef2c, Myocyte Enhancer Factor 2C; NLRP3, NOD-, LRR- and pyrin domain-containing protein 3; PARP-1, Poly [ADP-ribose] polymerase 1; PBMCs, Peripheral blood mononuclear cell; RhoB, Rho-related GTP binding protein; STAT3, Signal transducer and activator of transcription 3; TAB2, TGF-Beta Activated Kinase 1 (MAP3K7) Binding Protein 2; TGFBR3, Transforming growth factor beta receptor III; TRAF6, TGF-beta activated kinase 1 binding protein 2.